سعر سبارسين 200مجم 6 اقراص 2026

Sparcin 200mg 6 f.c. tab (Global Napi Pharmaceuticals > EMA Pharm, Egypt): sparfloxacin 200 mg film-coated tablets, a fluoroquinolone antibacterial; pack of 6.

• Adults (18 years and over): community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis caused by susceptible organisms.Population: Adults 18 years and overU.S. Food and Drug Administration (Drugs@FDA)

• Most frequent (at least 1%) in US phase 3 trials: photosensitivity reaction (7.9%), diarrhoea (4.6%), nausea (4.3%), headache (4.2%), dyspepsia, dizziness, insomnia, abdominal pain, pruritus, taste perversion, QTc prolongation (1.3%), vomiting, flatulence, vasodilatation.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• History of hypersensitivity or photosensitivity reactions.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Known QTc prolongation, or concomitant QTc-prolonging antiarrhythmics (class Ia such as quinidine/procainamide, class III such as sotalol/amiodarone, disopyramide, bepridil) or other drugs causing torsade de pointes.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Patients whose lifestyle or work does not allow avoidance of sun, bright light and UV exposure during treatment and for 5 days afterwards.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• Moderate to severe phototoxic reactions have occurred with direct, indirect or artificial UV light, even through glass or in cloudy weather; stop treatment at the first signs of phototoxicity.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Sparfloxacin can prolong the QTc interval.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• Aluminium/magnesium antacids, sucralfateForm chelation complexes that reduce sparfloxacin absorption; take these 4 hours after sparfloxacin.U.S. Food and Drug Administration (Drugs@FDA)
• QTc-prolonging drugs (class Ia/III antiarrhythmics, disopyramide, bepridil, terfenadine)Contraindicated combination because of torsade de pointes risk.U.S. Food and Drug Administration (Drugs@FDA)

• No adequate and well-controlled studies in pregnant women; use in pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Sparfloxacin is excreted in human milk; decide whether to stop nursing or stop the drug, considering its importance to the mother.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• Sparfloxacin: Fluoroquinolone that inhibits bacterial DNA gyrase/topoisomerase, blocking bacterial DNA replication.